Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Influsplit™ Tetra (Fluarix™ Tetra)
Influsplit Tetra · 1 trial · 1 indication
HI antibody titres were expressed as geometric mean titers (GMTs) and adjusted GMT ratios (Control Group/Co-Ad Group). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), FluA/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).
Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) and adjusted GMC ratio (Control Group/Co-Ad Group).
| Arm | Type | Description |
|---|---|---|
| Co-Ad Group | EXPERIMENTAL | Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28. |
| Control Group | EXPERIMENTAL | Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28. |
| Name | Type | Description |
|---|---|---|
| Influsplit™ Tetra (Fluarix™ Tetra) | BIOLOGICAL | Intramuscular injection, 1 dose each in Control and Co-Ad groups. |
| Pneumovax™ 23 | BIOLOGICAL | Intramuscular injection, 1 dose each in Control and Co-Ad groups. |
| Placebo (Saline) | BIOLOGICAL | Intramuscular injection, 1 dose each in Control and Co-Ad groups. |
Inclusion Criteria: * Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits). * A male or female aged 50 years or above at the time of the first vaccination at risk for complicatio...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
Influsplit Tetra is a quadrivalent influenza vaccine developed by GSK plc for the prevention of influenza. It is also known as Fluarix Tetra. The vaccine is designed to protect against influenza and has been evaluated in a Phase 3 clinical trial in adults aged 50 years and older.
Influsplit Tetra is used for the prevention of influenza. It is a quadrivalent influenza vaccine, meaning it targets multiple influenza strains. The vaccine is indicated for use in adults, particularly those 50 years of age and older, as studied in its clinical trial.
Influsplit Tetra is made by GSK plc, a global pharmaceutical company. GSK is listed on the stock exchange under the ticker symbol GSK. The company develops and manufactures the vaccine as part of its infectious disease portfolio.
Influsplit Tetra has been studied in a Phase 3 clinical trial. The trial has been completed. As a vaccine candidate, it is in late-stage clinical development. The Phase 3 trial evaluated its immunogenicity and safety in adults 50 years of age and older.
Influsplit Tetra has been evaluated in a Phase 3 clinical trial identified as NCT02218697. The trial was titled "Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit Tetra (Fluarix Tetra) (GSK2321138A) When Co-administered With Pneumovax 23 in Adults 50 Years of Age and Older." It was completed and enrolled 357 participants.
Yes, Influsplit Tetra is also known as Fluarix Tetra. The names refer to the same quadrivalent influenza vaccine developed by GSK plc. Influsplit Tetra is a trademarked name, and Fluarix Tetra is an alternative name used for the same product.